Global safety in adalimumab (HUMIRA®) rheumatoid arthritis clinical trials.

被引：0
|
作者：
Schiff, MH
Burmester, GR
Pangan, AL
Kupper, H
Spencer-Green, GT
机构：
[1] Denver Arthrit Clin PC, Denver, CO USA
[2] Univ Klinikum, Charite, Berlin, Germany
[3] Abbott Labs, Abbott Pk, IL 60064 USA
[4] Abbott Labs, Ludwigshafen, Germany
来源：
ARTHRITIS AND RHEUMATISM | 2004年 / 50卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S562 / S562
页数：1
相关论文
共 50 条
  • [31] Safety of Adalimumab in Global Clinical Trials of Ulcerative Colitis Patients
    Colombel, Jean-Frederic
    Ghosh, Subrata
    Sandborn, William
    Van Assche, Gert A.
    Reinisch, Walter
    Lazar, Andreas
    Eichner, Samantha
    Huang, Bidan
    Robinson, Anne
    Thakkar, Roopal
    GASTROENTEROLOGY, 2013, 144 (05) : S231 - S232
  • [32] Efficacy and safety of adalimumab (Humira®) as the second or third TNF antagonist used to treat patients with active rheumatoid arthritis (RA) in clinical practice.
    Bombardieri, S.
    Drosos, A. A.
    Malaise, M. G.
    Oezer, U.
    Kupper, H.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S411 - S411
  • [33] A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
    Fleischmann, Roy M.
    Alten, Rieke
    Pileckyte, Margarita
    Lobello, Kasia
    Hua, Steven Y.
    Cronenberger, Carol
    Alvarez, Daniel
    Bock, Amy E.
    Sewell, K. Lea
    ARTHRITIS RESEARCH & THERAPY, 2018, 20
  • [34] A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
    Roy M. Fleischmann
    Rieke Alten
    Margarita Pileckyte
    Kasia Lobello
    Steven Y. Hua
    Carol Cronenberger
    Daniel Alvarez
    Amy E. Bock
    K. Lea Sewell
    Arthritis Research & Therapy, 20
  • [35] Analysis of the US postmarketing safety of adalimumab (HUMIRA®) in patients with rheumatoid arthritis during the first 2 years after approval
    Kent, JD
    Pangan, AL
    Fitzpatrick, SB
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 415 - 415
  • [36] Factors affecting rheumatoid arthritis (RA) patients' decisions to participate in clinical trials.
    Lee, SJ
    Lenert, L
    Kavanaugh, A
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S127 - S127
  • [37] LONG-TERM SAFETY OF ADALIMUMAB IN PATIENTS FROM GLOBAL CLINICAL TRIALS IN RHEUMATOID ARTHRITIS, JUVENILE IDIOPATHIC ARTHRITIS, ANKYLOSING SPONDYLITIS, PSORIATIC ARTHRITIS, PSORIASIS, AND CROHN'S DISEASE
    Burmester, G. R.
    Panaccione, R.
    Gordon, K. B.
    McIlraith, M. J.
    Lacerda, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 514 - 515
  • [38] Sustained efficacy of adalimumab (HUMIRA™) plus methotrexate in rheumatoid arthritis (RA) patients.
    Schiff, MH
    Weisman, MH
    Furst, DE
    Kavanaugh, A
    Fischkoff, SA
    Spencer-Green, GT
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S314 - S315
  • [39] Cost-effectiveness of adalimumab (Humira™) in the treatment of US patients with rheumatoid arthritis (RA)
    Bansback, N
    Brennan, A
    Sengupta, N
    VALUE IN HEALTH, 2004, 7 (03) : 241 - 241
  • [40] Adalimumab (HUMIRA®) monotherapy significantly improves fatigue in patients with severe rheumatoid arthritis (RA)
    Dietz, BM
    Sterz, R
    Holtbrügge, W
    Kupper, H
    Van de Putte, LBA
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 392 - +
12345